According to the Zhitong Finance App, Fengyuan Pharmaceutical (000153.SZ) issued an announcement. Recently, the company received the “Drug Registration Certificate” for the concentrated solution of tirofiban hydrochloride for injection approved and issued by the State Drug Administration. Tirofiban hydrochloride injectable concentrated solution is used to prevent early myocardial infarction in adult patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) within 12 hours of the last episode of chest pain accompanied by ECG changes and/or elevated myocardial enzymes. Used for patients with acute myocardial infarction (STEMI) planning direct PCI to reduce the occurrence of major cardiovascular events.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.